OncoPharm

Latest Episodes:

ASCO 2024 Jun 06, 2024

Show notes

Lots and lots of updates from the past weekend's ASCO annual meeting. 1. ADRIATIC (consolidation durvalumab in limited stage SCLC) 2. NADINA (neoadjuvant Nivo/Ipi in stage III melanoma) 3. *NICHE-2 (neoadjuvant Nivo/Ipi in dMMR colon cancer) 4. CheckMate 8HW (Nivo/Ipi in dMMR metastatic colon cancer) 5. TRANSMET (liver transplantation in colon cancer with liver mets) 6. Eposec (FLOT > CROSS in adenocarcinoma of the esophagus) 7. LAURA (forever osimertinib in stage III EGFR-mutated NSCLC post-chemoRT) 8. CROWN (5 year update of lorlatinib in ALK+ NSCLC) 9. Destiny Breast-06 (T-DXd vs. chemo in HER-2 low and "ultra" low MBC who haven't received chemo in metastatic setting) 10. ASC4FIRST (Asciminib first line in CML. Funny title, amirite?)

Updated ASCO-ONS Antineoplastic Safety Standards May 30, 2024

Show notes

ASCO & ONS (along with pharmacist representation) released updated safety standards for preparing, administering, and monitoring chemotherapy. Look for a calendar invitation to review your site's policies soon. Link: https://doi.org/10.1200/OP.24.00216

Tarlatamab May 23, 2024

Show notes

A new drug for small-cell lung cancer, a bispecific, targeting DLL3 on small-cell lung cancer and CD3 on T-cells is FDA approved. But, infigratinib's FDA approval for cholangiocarcinoma is withdrawn.

QT Prolongation In Oncology May 16, 2024

Show notes

QT interval prolongation is a common hurdle to taking care of cancer patients. We dive into what QT interval prolongation is, why it matters, risk factors, and prevention/management strategies.

Pro-MACE-CytaBOM May 09, 2024

Show notes

The non-Award Winning series of Landmarks in OncoPharm returns to discuss a Next Big Thing in NHL that wasn't any better than plain old CHOP. From April 1993, it's Pro-MACE-CytaBOM Link: https://www.nejm.org/doi/full/10.1056/NEJM199304083281404

Tisotumab Vedotin, HD Mtx In CNS Lymphoma & Class III BRAF Mutations May 02, 2024

Show notes

Tisotumab vedotin garners a regular FDA approval for metastatic cervical cancer with OS benefit data. A lingering question that demands a focused RCT: What is the optimal dose of methotrexate in primary CNS lymphoma? I'm glad I'm not the only one with this question: https://doi.org/10.1177/10781552231176754 What, some BRAF mutations in colorectal cancer might respond to EGFR-mab therapy? https://doi.org/10.1200/OP.21.00160

Late April Updates Apr 25, 2024

Show notes

Lots of recent updates to cover this week... 1. Adjuvant pembrolizumab of RCC demonstrates OS improvement in NEJM publication (DOI: 10.1056/NEJMoa2312695) 2. Yet adjuvant nivolumab did not demonstrate OS improvement in the adjuvant setting. There may be a few reasons for this (https://doi.org/10.1200/JCO.2024.42.4_suppl.LBA358) 3. A cytokine-fusion protein, nogapendekin alfa inbakicept, is approved for intravesicular use in BCG-unresponsive bladder cancer. This agent appears to activity in NSCLC too... 4. The Phase II APPLE trial provides some evidence than deferring osimertinib to the second-line setting in metastatic EGFR-mutated NSCLC may yield similar OS to first-line use of osimertinib. (https://doi.org/10.1200/JCO.23.01521) 5.The METALLICA study provides a nice roadmap for empiric metformin use when starting alpelisib (https://doi.org/10.1016/j.eclinm.2024.102520) 6. Does CPX-351 cause less intestinal damage than 7 + 3? And could that explain the discordance between time of neutropenia and infection rates? A mouse model suggests yes. (https://doi.org/10.1200/jco.2017.77.6112)

NSCLC In A Nutshell Apr 19, 2024

Show notes

Arguably, the most anticipated release of 4/19/24

HOPA '24, Site Agnositc T-DXd, & ALINA Apr 11, 2024

Show notes

What I learned (or relearned?) at HOPA's 2024 Annual Conference: updates in Neuro Oncology, fedratinib toxicity, and bispecific antibodies in multiple myeloma. Also, fam-trastuzumab deruxtecan (T-DXd) garnered a site-agnostic approval for HER2 amplified solid tumors. Finally, the ALINA study, adjuvant alectinib in ALK+ NSCLC, was published in this week's NEJM.

Tumor Lysis Syndrome Apr 04, 2024

Show notes

Tumor Lysis Syndrome (TLS) is a foundational topic for all oncology clinicians. We discuss the what, the why, prevention, and treatment.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected